0001209191-17-041630.txt : 20170623
0001209191-17-041630.hdr.sgml : 20170623
20170623160351
ACCESSION NUMBER: 0001209191-17-041630
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20170614
FILED AS OF DATE: 20170623
DATE AS OF CHANGE: 20170623
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CELGENE CORP /DE/
CENTRAL INDEX KEY: 0000816284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 222711928
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
BUSINESS PHONE: (908)673-9000
MAIL ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Curran Terrie
CENTRAL INDEX KEY: 0001690298
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34912
FILM NUMBER: 17927600
MAIL ADDRESS:
STREET 1: C/O MYOVANT SCIENCES INC.
STREET 2: 320 WEST 37TH STREET, 5TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10018
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2017-06-14
0
0000816284
CELGENE CORP /DE/
CELG
0001690298
Curran Terrie
86 MORRIS AVENUE
SUMMIT
NJ
07901
0
1
0
0
See remarks
Common Stock
4710
D
Common Stock
599
I
401(k) Plan
Stock Option (right to buy)
58.33
2023-05-01
Common Stock
6572
D
Stock Option (right to buy)
58.33
2023-05-01
Common Stock
3428
D
Stock Option (right to buy)
81.56
2023-12-02
Common Stock
3750
D
Stock Option (right to buy)
87.64
2024-07-28
Common Stock
6359
D
Stock Option (right to buy)
87.64
2024-07-28
Common Stock
1141
D
Stock Option (right to buy)
103.10
2024-10-27
Common Stock
5000
D
Stock Option (right to buy)
117.18
2024-12-19
Common Stock
7050
D
Stock Option (right to buy)
118.57
2025-02-02
Common Stock
4157
D
Stock Option (right to buy)
118.57
2025-02-02
Common Stock
843
D
Stock Option (right to buy)
109.90
2025-05-04
Common Stock
2500
D
Stock Option (right to buy)
132.56
2025-07-27
Common Stock
2500
D
Stock Option (right to buy)
114.08
2025-11-09
Common Stock
2500
D
Stock Option (right to buy)
100.80
2026-02-01
Common Stock
1875
D
Stock Option (right to buy)
100.80
2026-02-01
Common Stock
625
D
Stock Option (right to buy)
104.97
2026-05-02
Common Stock
2773
D
Stock Option (right to buy)
104.97
2026-05-02
Common Stock
352
D
Stock Option (right to buy)
114.69
2026-08-01
Common Stock
3125
D
Stock Option (right to buy)
102.18
2026-10-31
Common Stock
6562
D
Stock Option (right to buy)
113.18
2027-01-30
Common Stock
5680
D
Stock Option (right to buy)
113.18
2027-01-30
Common Stock
883
D
Stock Option (right to buy)
124.06
2027-05-01
Common Stock
6776
D
Restricted Stock Unit
Common Stock
1500
D
Restricted Stock Unit
Common Stock
1765
D
Restricted Stock Unit
Common Stock
2500
D
Restricted Stock Unit
Common Stock
2500
D
Restricted Stock Unit
Common Stock
1563
D
Restricted Stock Unit
Common Stock
3281
D
Restricted Stock Unit
Common Stock
3426
D
The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated as of April 15, 2015)).
The option is immediately exercisable and is fully vested.
The option is immediately exercisable and will fully vest on December 2, 2017.
The option is immediately exercisable and will vest in two annual installments as follows: 2,500 shares on July 28, 2017 and 1,359 shares on July 28, 2018.
The option is immediately exercisable and will fully vest on July 28, 2018.
The option is immediately exercisable and will vest in two equal annual installments commencing on October 27, 2017.
The option is immediately exercisable and will vest in two annual installments as follows: 1,763 shares on December 19, 2017 and 1,763 shares on December 19, 2018.
The option is immediately exercisable and will vest in two annual installments as follows: 1,250 shares on February 2, 2018 and 407 shares on February 2, 2019.
The option is immediately exercisable and will fully vest on February 2, 2019.
The option is immediately exercisable and will vest in two equal annual installments commencing on May 4, 2018.
The option is immediately exercisable and will vest in three equal annual installments commencing on July 27, 2017.
The option is immediately exercisable and will vest in three equal annual installments commencing on November 9, 2017.
The option is immediately exercisable and will vest in two equal annual installments commencing on on February 1, 2018.
The option is immediately exercisable and will fully vest on February 1, 2020.
The option is immediately exercisable and will vest in three annual installments as follows: 781 shares on May 2, 2018, 781 shares on May 2, 2019, and 430 shares on May 2, 2020.
The option is immediately exercisable and will fully vest on May 2, 2020.
The option is immediately exercisable and will vest in four annual installments as follows: 781 shares on August 1, 2017, 781 shares on August 1, 2018, 781 shares on August 1, 2019, and 782 shares on August 1, 2020.
The option is immediately exercisable and will vest in four annual installments as follows: 1,640 shares on October 31, 2017; 1,640 shares on October 31, 2018; 1,641 shares on October 31, 2019, and 1,641 shares on October 31, 2020.
The option is immediately exercisable and will vest in four annual installments as follows: 1,640 shares on January 30, 2018, 1,641 shares on January 30, 2019, 1,641 shares on January 30, 2020, and 758 shares on January 30, 2021.
The option is immediately exercisable and will fully vest on January 30, 2021.
The option is immediately exercisable and will vest in four equal annual installments commencing on May 1, 2018.
The restricted stock units will vest on August 1, 2017. Vested shares will be delivered to the reporting person promptly after the vesting date.
The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated as of April 15, 2015)).
Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
The restricted stock units will vest on December 19, 2017. Vested shares will be delivered to the reporting person on the vesting date.
The restricted stock units will vest on May 4, 2018. Vested shares will be delivered to the reporting person on the vesting date.
The restricted stock units will vest on December 16, 2018. Vested shares will be delivered to the reporting person on the vesting date.
The restricted stock units will vest on May 2, 2019. Vested shares will be delivered to the reporting person on the vesting date.
The restricted stock units will vest on October 31, 2019. Vested shares will be delivered to the reporting person on the vesting date.
The restricted stock units will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date.
President Inflammation & Immunology
/s/ Terrie J. Curran
2017-06-23
EX-24.3_732986
2
poa.txt
POA DOCUMENT
LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS
Know all by these presents, that the undersigned hereby constitutes and appoints
each of Robert J. Hugin, Mark J. Alles and Peter N. Kellogg the undersigned's
true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or director of Celgene Corporation (the "Company"), Forms 3,
4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934
and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4, or 5,
complete and execute any amendment or amendments thereto, and timely file such
form with the United States Securities and Exchange Commission and any stock
exchange or similar authority; and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that each of the foregoing
attorney-in-fact, in serving in such capacity at the request of the undersigned,
is not assuming, nor is the Company assuming, any of the undersigned's
responsibilities to comply with Section 16 of the Securities Exchange Act of
1934.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.
/s/ Terrie J. Curran June 23, 2017